ACTRN12608000602325已完成1 期
A Phase 1, Open Label, Single-Center, Dose-Escalation, Cohort Study to Determine the Safety, Pharmacodynamics and Pharmacokinetics of a Single Intravenous (IV) Injection of PF0713 in Healthy Subjects
PharmacoFore, Inc.0 个研究点目标入组 39 人开始时间: 2008年12月3日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 39
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 50 Years（—）
- 性别
- Male
入选标准
- •Body mass index between 18 and 30 kg/m^2, blood pressure between 100-140/60-90 mmHg, heart rate between 50-99 beats per minute
排除标准
- •Problems with anesthesia, allergy or sensitivity to propofol or components of the formulation, regular tobacco use, alcohol or drug abuse in the past 2 years, enrollment in an investigational drug study within 30 days, American Society of Anesthesiologists Physical Status Classification greater than II.
研究者
相似试验
已完成
1 期
A Phase I, Open-Label, Pharmacokinetic Study of ivabradine in healthy Chinese volunteersChronic Stable Angina PectorisCardiovascular - Coronary heart diseaseACTRN12613000277741Jiangsu Hengrui Medicine Co,. Ltd36
已完成
1 期
A Phase I, Open-Label, Pharmacokinetic Study of tolvaptan in healthy Chinese volunteershyponatremiaCardiovascular - Other cardiovascular diseasesMetabolic and Endocrine - Other metabolic disordersACTRN12616000207415Fuwai hospital72
进行中（未招募）
1 期
A Phase 1, Open-label , Dose EscalationStudy of Berubicin® in Pediatric Patientswith Progressive, Refractory, or Recurrent High GradeGliomasEUCTR2019-004016-58-PLWPD Pharmaceuticals Sp. z o.o.35
尚未招募
1 期
First in Human Multicenter Open Name Dose-increase,Consolidation method to Study Safety drug-level in Blood & drug metabolism Clinical Activity of Oral JBI-778 in Lung Cancer Patients with, without Brain Metastasis IDH Mutated WHO Grade 3,4 Recurrent Glioma, Salivary glands tumorCTRI/2024/07/070802Jubilant Therapeutics India Limited
未知
1 期
A Phase 1, Open-label, Single-arm, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-573, a Fully Human Monoclonal Antibody Directed Against Insulin-like Growth Factors 1 and 2, in Japanese Subjects With Advanced Solid Tumours Refractory to Standard Therapy or for Which No Standard Therapy ExistsJPRN-jRCT2080221544AstraZeneca